NCT05532943View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Allogeneic umbilical cord mesenchymal stem cells

UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.

BIOLOGICAL

Control group

Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.

Trial Locations (1)

404

RECRUITING

China Medical University Hospital, Taichung

All Listed Sponsors
lead

Ever Supreme Bio Technology Co., Ltd.

INDUSTRY